| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
ORIGINAL RESEARCH |
From the Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana.
Address reprint requests to: Mark Lakshmanan, MD, Lilly Research Laboratories, Lilly Corporate Center, Indianopolis, IN 46285
Objective: To assess the incidence of adverse events in postmenopausal women treated with raloxifene compared with placebo, hormone replacement therapy (HRT), or unopposed estrogen.
Methods: Common treatment groups were pooled across eight randomized, parallel clinical trials (6–30 months’ duration) of raloxifene to create the following three databases: placebo-controlled, HRT-controlled, and estrogen-controlled databases. Incidence and severity of all treatment-emergent adverse events, defined as events that first occurred or worsened during treatment, were compared among groups in each of the databases.
Results: Discontinuation rates overall, and those related to adverse events, were not significantly different between treatment groups in any database. There was no significant difference in incidence of vaginal bleeding or breast discomfort between women treated with raloxifene (60 mg/d) or placebo. Both of these events were reported more frequently in women receiving HRT or estrogen. Vaginal bleeding was responsible for significantly more discontinuations from the HRT groups compared with the raloxifene group. Hot flashes was the only event common to all three databases that was significantly increased in the raloxifene group, but this event did not increase the discontinuation rates. The incidence of leg cramps was greater in raloxifene-treated women compared with placebo-treated women in the placebo-controlled database, but did not cause any discontinuations of therapy. Raloxifene had no effect on the incidence of vaginal symptoms or central nervous system events.
Conclusion: Raloxifene had an adverse event profile distinct from HRT and unopposed estrogen and was well tolerated by postmenopausal women.
This article has been cited by other articles:
|
|
 |
|
  A. J. Huang, D. Grady, V. L. Jacoby, T. L. Blackwell, D. C. Bauer, and G. F. Sawaya Persistent Hot Flushes in Older Postmenopausal Women Arch Intern Med, April 28, 2008; 168(8): 840 - 846. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Jakob, F. Marin, E. Martin-Mola, D. Torgerson, P. Fardellone, S. Adami, N.C. Thalassinos, D. Sykes, J. Melo-Gomes, C. Chinn, et al. Characterization of patients with an inadequate clinical outcome from osteoporosis therapy: the Observational Study of Severe Osteoporosis (OSSO) QJM, August 1, 2006; 99(8): 531 - 543. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. S. Komm, Y. P. Kharode, P. V. N. Bodine, H. A. Harris, C. P. Miller, and C. R. Lyttle Bazedoxifene Acetate: A Selective Estrogen Receptor Modulator with Improved Selectivity Endocrinology, September 1, 2005; 146(9): 3999 - 4008. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Ronkin, R. Northington, E. Baracat, M. G. Nunes, D. F. Archer, G. Constantine, and J. H. Pickar Endometrial Effects of Bazedoxifene Acetate, a Novel Selective Estrogen Receptor Modulator, in Postmenopausal Women Obstet. Gynecol., June 1, 2005; 105(6): 1397 - 1404. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. J. Fabian and B. F. Kimler Selective Estrogen-Receptor Modulators for Primary Prevention of Breast Cancer J. Clin. Oncol., March 10, 2005; 23(8): 1644 - 1655. [Full Text] [PDF]
|
|
|
|
 |
|
 S. Martino, J. A. Cauley, E. Barrett-Connor, T. J. Powles, J. Mershon, D. Disch, R. J. Secrest, S. R. Cummings, and For the CORE Investigators Continuing Outcomes Relevant to Evista: Breast Cancer Incidence in Postmenopausal Osteoporotic Women in a Randomized Trial of Raloxifene J Natl Cancer Inst, December 1, 2004; 96(23): 1751 - 1761. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Genitourinary Tract Changes Obstet. Gynecol., October 1, 2004; 104(4_suppl): 56S - 61S. [Full Text] [PDF]
|
|
|
|
 |
|
 J. A. Clowes, N. F. A. Peel, and R. Eastell The Impact of Monitoring on Adherence and Persistence with Antiresorptive Treatment for Postmenopausal Osteoporosis: A Randomized Controlled Trial J. Clin. Endocrinol. Metab., March 1, 2004; 89(3): 1117 - 1123. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. E. Waetjen, J. S. Brown, K. Modelska, T. Blackwell, E. Vittinghoff, and S. R. Cummings Effect of Raloxifene on Urinary Incontinence: A Randomized Controlled Trial Obstet. Gynecol., February 1, 2004; 103(2): 261 - 266. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. W. DRAPER The Role of Selective Estrogen Receptor Modulators (SERMs) in Postmenopausal Health Ann. N.Y. Acad. Sci., November 1, 2003; 997(1): 373 - 377. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. W. C. Kung, H.-T. Chao, K.-E. Huang, A. G. Need, N. Taechakraichana, F.-H. Loh, F. Gonzaga, U. Sriram, N. M. N. Ismail, A. Farooqi, et al. Efficacy and Safety of Raloxifene 60 Milligrams/Day in Postmenopausal Asian Women J. Clin. Endocrinol. Metab., July 1, 2003; 88(7): 3130 - 3136. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. P. Brown and R. G. Josse Lignes directrices de pratique clinique 2002 pour le diagnostic et le traitement de l'osteoporose au Canada Can. Med. Assoc. J., March 18, 2003; 168(90060): SF1 - 38. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Parsons, D. Merritt, A. Rosen, H. Heath III, S. Siddhanti, and L. Plouffe Jr Effect of Raloxifene on the Response to Conjugated Estrogen Vaginal Cream or Nonhormonal Moisturizers in Postmenopausal Vaginal Atrophy Obstet. Gynecol., February 1, 2003; 101(2): 346 - 352. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Palomba, F. G. Numis, G. Mossetti, D. Rendina, P. Vuotto, T. Russo, F. Zullo, C. Nappi, and V. Nunziata Raloxifene administration in post-menopausal women with osteoporosis: effect of different BsmI vitamin D receptor genotypes Hum. Reprod., January 1, 2003; 18(1): 192 - 198. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. P. Brown and R. G. Josse 2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada Can. Med. Assoc. J., November 12, 2002; 167(90100): s1 - 34. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Grady A 60-Year-Old Woman Trying to Discontinue Hormone Replacement Therapy JAMA, April 24, 2002; 287(16): 2130 - 2137. [Full Text] [PDF]
|
|
|
|
|
|
S. L. HENDRIX and S. G. McNEELEY Effect of Selective Estrogen Receptor Modulators on Reproductive Tissues Other Than Endometrium Ann. N.Y. Acad. Sci., December 1, 2001; 949(1): 243 - 250. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. ANTHONY, J. K. WILLIAMS, and B. K. DUNN What Would Be the Properties of an Ideal SERM? Ann. N.Y. Acad. Sci., December 1, 2001; 949(1): 261 - 278. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. BARRETT-CONNOR Raloxifene: Risks and Benefits Ann. N.Y. Acad. Sci., December 1, 2001; 949(1): 295 - 303. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. S. KOMM and C. R. LYTTLE Developing a SERM: Stringent Preclinical Selection Criteria Leading to an Acceptable Candidate (WAY-140424) for Clinical Evaluation Ann. N.Y. Acad. Sci., December 1, 2001; 949(1): 317 - 326. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. R. Goldstein, P. Neven, L. Zhou, Y. L. Taylor, A. V. Ciaccia, and L. Plouffe Jr Raloxifene Effect on Frequency of Surgery for Pelvic Floor Relaxation Obstet. Gynecol., July 1, 2001; 98(1): 91 - 96. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. E. Lippman, K. A. Krueger, S. Eckert, A. Sashegyi, E. L. Walls, S. Jamal, J. A. Cauley, and S. R. Cummings Indicators of Lifetime Estrogen Exposure: Effect on Breast Cancer Incidence and Interaction With Raloxifene Therapy in the Multiple Outcomes of Raloxifene Evaluation Study Participants J. Clin. Oncol., June 15, 2001; 19(12): 3111 - 3116. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Clarke, F. Leonessa, J. N. Welch, and T. C. Skaar Cellular and Molecular Pharmacology of Antiestrogen Action and Resistance Pharmacol. Rev., March 1, 2001; 53(1): 25 - 72. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. louffe Jr. Selective Estrogen Receptor Modulators (SERMs) in Clinical Practice Reproductive Sciences, January 1, 2000; 7(1_suppl): S38 - S46. [Abstract] [PDF]
|
|
|
|
|
|
A. L. Franks and K. K. Steinberg Encouraging News From the SERM Frontier JAMA, June 16, 1999; 281(23): 2243 - 2244. [Full Text] [PDF]
|
|
|
|
 |
|
 J. An, C. Tzagarakis-Foster, T. C. Scharschmidt, N. Lomri, and D. C. Leitman Estrogen Receptor beta -Selective Transcriptional Activity and Recruitment of Coregulators by Phytoestrogens J. Biol. Chem., May 18, 2001; 276(21): 17808 - 17814. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
